Cullinan rises as early-stage data show remission in autoimmune disease drugs
BUZZ-Cullinan rises as early-stage data show remission in autoimmune disease drugs ** Shares of biotech firm Cullinan Therapeutics CGEM.O rise 5.39% to $13.89
** Co says CLN-978 showed remission in a rheumatoid arthritis patient within four weeks and reduced disease-causing antibodies
** CGEM's velinotamig, an experimental drug, led to complete kidney response in two lupus nephritis patients, a condition that damages the kidneys, co says
** Co says drugs target autoimmune diseases where the immune system attacks the body, leading to joint pain in rheumatoid arthritis and organ damage in lupus
** No serious side effects reported across both early-stage studies, co says
** Co plans to expand trials into more diseases including blood disorders and share more data later this year, co says
** Including session's move, stock up ~34% YTD
(Reporting by Sahil Pandey in Bengaluru)